Germ cell tumour presenting as left atrial mass

2018 ◽  
Vol 6 (1) ◽  
pp. 20
Author(s):  
AnilRamesh Jawahirani ◽  
Dilip Kshirsagar ◽  
Deepak Jeswani ◽  
Vivek Gupta

2019 ◽  
Author(s):  
Suhaniya Samarasinghe ◽  
Rebecca Scott ◽  
Michael J Seckl ◽  
Mike Gonzalez ◽  
Richard Harvey ◽  
...  


2021 ◽  
Vol 5 (2) ◽  
Author(s):  
Toshimitsu Kato ◽  
Noriaki Takama ◽  
Tomonari Harada ◽  
Tomonobu Abe


2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii282-iii282
Author(s):  
Rafael Moleron ◽  
Sara Stoneham ◽  
Thankamma Ajithkumar ◽  
Justin Cross ◽  
James Nicholson ◽  
...  

Abstract INTRODUCTION Patients with localised CNS-germinoma have excellent survival. More recently, intensive inpatient chemotherapy (carboPEI=carboplatin/etoposide/ifosfamide in Europe) has been effectively employed to reduce radiotherapy fields and/or dose. Current research priorities focus on reducing treatment burden and long-term sequelae. Of note, outpatient-based single-agent carboplatin chemotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathology) [Alifrangis,EJC,2020]. Recently, successful vinblastine monotherapy was reported in localised CNS-germinoma [Murray,Neurooncol-Adv,2020]. METHODS Due to the COVID-19 pandemic, adapted UK guidelines for germ-cell-tumour management were distributed, including potential non-standard treatment options that would reduce hospital visits/admissions. A 30-year-old patient presented with a 32mmx30mmx35mm diameter solid+multi-cystic localised pineal CNS lesion, consistent radiologically with a germ-cell-tumour with prominent teratoma component. Investigation revealed negative AFP/HCG markers and biopsy-proven pure germinoma. After appropriate consent, the patient commenced 12-week induction with weekly vinblastine monotherapy (low-grade-glioma dosing [Lassaletta,JCO,2016]), with wk6&12 MRI re-assessment prior to definitive radiotherapy. RESULTS Vinblastine was well-tolerated. After initial 4mg/m2 test-dosing (wk1), standard 6mg/m2 was delivered for wk2, but resulted in asymptomatic neutropenia (nadir 0.3x10^9/l) and missed dosing at wk3. Subsequent doses were 4mg/m2, with no further neutropenia. As expected, MRI showed moderate 40% tumour volume reduction by wk12. Surgical resection of the residual presumed teratoma component was undertaken prior to radiotherapy. CONCLUSION Patients with CNS-germinoma have excellent outcomes and reduction of treatment-effects remains a priority. The exquisite chemosensitivity of germinoma, excellent results from monotherapy for metastatic testicular disease, and early promise of vinblastine monotherapy lend itself to further exploration for CNS-germinoma.



1989 ◽  
Vol 59 (2) ◽  
pp. 156-159 ◽  
Author(s):  
A Horwich




2012 ◽  
Vol 22 (2) ◽  
pp. 86-87 ◽  
Author(s):  
Sait Demirkol ◽  
Oben Baysan ◽  
Turgay Celik ◽  
Bulent Karaman ◽  
Seyfettin Gumus


2012 ◽  
Vol 62 (2) ◽  
pp. 360-363 ◽  
Author(s):  
Jessica A Clevenger ◽  
Jennifer B Kum ◽  
Riley E Alexander ◽  
David J Grignon ◽  
Liang Cheng ◽  
...  




2021 ◽  
Author(s):  
Jonathan Dillon


Sign in / Sign up

Export Citation Format

Share Document